Royalty Pharma plc
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.
Royalty Pharma (RPRX) agreed to pay Zealand Pharma $100M for future royalties on rusfertide, an experimental treatment for polycythemia vera. The deal includes a 1% royalty on global sales, with $50M paid at closing and the rest after a year. Rusfertide's FDA decision is expected in Q3 2026. RPRX's Q2 2026 royalty receipts grew 14% to $768M, and it raised its full-year guidance to $3.4B-$3.5B. The company has $9.2B in debt and expects $350M-$360M in interest payments for 2026.
Royalty Pharma (RPRX) agreed to a $100M deal with Zealand Pharma for rights to a rare blood disorder therapy. RPRX shares are down 1.86% to $60.58, but up 11.16% over 90 days and 70.08% over a year. Analysts debate its valuation, with some calling it 2% overvalued at $59.25, while a DCF model suggests it's heavily discounted at $195.31.
Over the past 7 days, alphai's AI scored 2 news stories mentioning RPRX (Royalty Pharma plc). Coverage has skewed bullish: 1 bullish, 1 neutral, and 0 bearish.
Recent RPRX coverage spans earnings, financial news and corporate actions.
In the last 30 days, RPRX insiders filed 3 SEC Form 4 transactions — no purchases and 3 sales ($6.6M). The most active reporter was Coyne Terrance P., EVP & CFO, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Strong royalty growth and new funding partnership.
The royalty purchase adds upside potential if FDA approval is granted, but caps upside at $1.5 B sales.
The $100 M royalty financing boosts RPRX's near‑term cash flow and expands its royalty portfolio.
The insider sale represents a modest $6 M divestiture, likely reflecting personal liquidity rather than a negative signal about the company.
This is a routine, pre-arranged insider sale with limited standalone signal, but it can slightly affect near-term sentiment and positioning.
alphai scores every news story that mentions RPRX with an AI model for sentiment and relevance, and aggregates insider trades from Royalty Pharma plc's SEC EDGAR Form 4 filings. Figures refresh continuously.
Several biotech stocks hit 52-week highs on September 1, 2026. MiniMed Group (MMED) rose 10% to $22.74 with 16.6% sales growth. Pulse Biosciences (PLSE) gained 3% to $54.39. Solventum (SOLV) reached $94.16 with 2.2% revenue growth. Royalty Pharma (RPRX) climbed to $62.58 with 14% royalty receipts growth. Apogee Therapeutics (APGE) hit $135.09 and will be acquired by AbbVie for $10.9B.
2 min readRoyalty Pharma (RPRX) agreed to pay Zealand Pharma $100M for future royalties on rusfertide, an experimental treatment for polycythemia vera. The deal includes a 1% royalty on global sales, with $50M paid at closing and the rest after a year. Rusfertide's FDA decision is expected in Q3 2026. RPRX's Q2 2026 royalty receipts grew 14% to $768M, and it raised its full-year guidance to $3.4B-$3.5B. The company has $9.2B in debt and expects $350M-$360M in interest payments for 2026.
2 min readRoyalty Pharma (RPRX) agreed to a $100M deal with Zealand Pharma for rights to a rare blood disorder therapy. RPRX shares are down 1.86% to $60.58, but up 11.16% over 90 days and 70.08% over a year. Analysts debate its valuation, with some calling it 2% overvalued at $59.25, while a DCF model suggests it's heavily discounted at $195.31.
2 min readRoyalty Pharma (RPRX) EVP & Chairman Christopher Hite sold 100,000 shares via a 10b5-1 plan at $59.9725 each, leaving 370,401 indirectly held. He also donated 16,800 shares to Lehigh University, retaining 23,200 directly. Family vehicles hold convertible interests.
1 min readHite Christopher (EVP & Chairman, Partnering) sold 100,000 indirectly-held shares of Royalty Pharma plc (RPRX) at $59.97 ($6.00M total) on 2026-08-18 under a Rule 10b5-1 trading plan.
1 min readCoyne Terrance P. (EVP & CFO) sold 11,002 indirectly-held shares of Royalty Pharma plc (RPRX) at an average of $58.68 ($58.59–$59.14, $0.65M total) across 2 trades on 2026-08-13 under a Rule 10b5-1 trading plan.
2 min readRoyalty Pharma (RPRX) agreed to pay Neurimmune up to $425 million for a 3% to 4% royalty on AstraZeneca (AZN) candidate cliramitug, including $125 million upfront and $125 million in 2027 plus $175 million tied to clinical and regulatory milestones. Cliramitug is in Phase 3 DepleTTR-CM with readouts expected in 2028. RPRX Q1 2026 Portfolio Receipts rose 10% to $925 million; AZN H1 2026 revenue rose 6% and core profit/EPS rose 11%.
6 min readRoyalty Pharma (RPRX) reported Q2 net income attributable to the company fell to $18 million from $32 million a year earlier. Adjusted EBITDA rose to $736 million from $633 million. Royalty Receipts grew 14% to $768 million, and Portfolio Receipts rose 6% to $773 million. The company raised 2026 Portfolio Receipts guidance to $3.400 billion to $3.500 billion.
2 min readRoyalty Pharma plc (RPRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Press Release August 5, 2026 R oyalty Pharma reports second quarter 2026 results Portfolio Rece ipts growth o f 6% to $773 million ; Royalty Receipts growth of 14% Net cash provided by operating activities of $728 million Raised f ull year 2026 guidance: Portfolio Receipts expect
7 min readRoyalty Pharma plc said it will appoint Greg Raskin, M.D. as Senior Vice President, Head of Academic Initiatives, effective August 2026. He will lead outreach to academic and non-profit institutions and oversee the Royalty Pharma Translational Prize. The company noted he previously worked at Memorial Sloan Kettering and AllianceBernstein.
2 min read
